 LAVAL, QC , ROCKVILLE, MD and CAMBRIDGE, UK , Nov. 25, 2019 CNW Telbec - Liminal BioSciences Inc. NASDAQ: LMNL TSX: LMNL Liminal BioSciences or the Company, a clinical-stage biopharmaceutical company focused on developing novel therapeutics to treat unmet needs in patients with liver, respiratory and kidney disease, announced today it has closed on the previously announced divestment of its Isle of Man -based bioseparations business operated through its subsidiary Prometic Bioseparations Ltd. PBL to KKR Co., a leading global investment firm KKR. We are very pleased to close on the sale of our bioseparations business to KKR said Kenneth Galbraith , the CEO of Liminal BioSciences. 